UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Kinase drug discovery 20 years after imatinib: progress and future directions

Nature reviews. Drug discovery, 2021-07, Vol.20 (7), p.551-569

2021

Volltextzugriff (PDF)

Kinase drug discovery 20 years after imatinib

Nature reviews. Drug discovery, 2022-04

2022

Volltextzugriff (PDF)

The quest to overcome resistance to EGFR-targeted therapies in cancer

Nature medicine, 2013-11, Vol.19 (11), p.1389-1400

2013

Volltextzugriff (PDF)

Evaluating TBK1 as a therapeutic target in cancers with activated IRF3

Molecular cancer research, 2014-07, Vol.12 (7), p.1055-1066

2014

Volltextzugriff (PDF)

False positive plasma genotyping due to clonal hematopoiesis

Clinical cancer research, 2018-09, Vol.24 (18), p.4437-4443

2018

Volltextzugriff (PDF)

Overcoming therapy resistance in EGFR-mutant lung cancer

Nature cancer, 2021-04, Vol.2 (4), p.377-391

2021

Volltextzugriff (PDF)

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Clinical cancer research, 2008-05, Vol.14 (10), p.2895-2899

2008

Volltextzugriff (PDF)

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

Clinical cancer research, 2021-07, Vol.27 (13), p.3528-3539

2021

Volltextzugriff (PDF)

The biology and treatment of EML4-ALK non-small cell lung cancer

European journal of cancer (1990), 2010-07, Vol.46 (10), p.1773-1780

2010

Volltextzugriff (PDF)

Targeting MET Dysregulation in Cancer

Cancer discovery, 2020-07, Vol.10 (7), p.922-934

2020

Volltextzugriff (PDF)

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3747-3761

2023

Volltextzugriff (PDF)

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Science (American Association for the Advancement of Science), 2007-05, Vol.316 (5827), p.1039-1043

2007

Volltextzugriff (PDF)

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Nature medicine, 2015-06, Vol.21 (6), p.560-562

2015

Volltextzugriff (PDF)

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

Journal of medicinal chemistry, 2018-05, Vol.61 (9), p.4249-4255

2018

Volltextzugriff (PDF)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-03, Vol.36 (9), p.841-849

2018

Volltextzugriff (PDF)

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2022-01, Vol.386 (3), p.241-251

2022

Volltextzugriff (PDF)

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Clinical cancer research, 2014-03, Vol.20 (6), p.1698-1705

2014

Volltextzugriff (PDF)

TGFβ pathway inhibition in the treatment of non-small cell lung cancer

Pharmacology & therapeutics (Oxford), 2018-04, Vol.184, p.112-130

2018

Volltextzugriff (PDF)

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1288-1296

2017

Volltextzugriff (PDF)

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1097-1104

2013

Volltextzugriff (PDF)

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-10, Vol.34 (28), p.3375-3382

2016

Volltextzugriff (PDF)

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Cancer research (Chicago, Ill.), 2017-05, Vol.77 (10), p.2712-2721

2017

Volltextzugriff (PDF)

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Cell, 2018-02, Vol.172 (4), p.857-868.e15

2018

Volltextzugriff (PDF)

Top advances of the year: Targeted therapy for lung cancer

Cancer, 2024-10, Vol.130 (19), p.3239-3250

2024

Volltextzugriff (PDF)

Lung cancer in patients who have never smoked — an emerging disease

Nature reviews. Clinical oncology, 2024-02, Vol.21 (2), p.121-146

2024

Volltextzugriff (PDF)

1 – 25 von 957

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(882)
Mit Volltextzugriff
(851)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(942)
Japanisch
(12)
Finnisch
(3)
Deutsch
(2)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(558)
Life Sciences & Biomedicine
(508)
Humans
(425)
Oncology
(325)
Lung Neoplasms - Drug Therapy
(203)
Female
(193)
Lung Neoplasms - Genetics
(193)
Mutation
(189)
Male
(187)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(173)
Carcinoma, Non-Small-Cell Lung - Genetics
(154)
Middle Aged
(149)
Biological And Medical Sciences
(147)
Aged
(140)
Medical Sciences
(136)
Lung Neoplasms - Pathology
(119)
Adult
(116)
Lung Cancer
(104)
Tumors
(97)
Animals
(93)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(152)
Cancer Research
(106)
Clinical Cancer Research
(79)
Journal Of Thoracic Oncology
(69)
Cancer Discovery
(27)
The New England Journal Of Medicine
(22)
Cancer
(19)
Lung Cancer
(18)
Molecular Cancer Therapeutics
(14)
Nature
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Kinase drug discovery 20 years after imatinib: progress and future directions

Kinase drug discovery 20 years after imatinib

The quest to overcome resistance to EGFR-targeted therapies in cancer

Evaluating TBK1 as a therapeutic target in cancers with activated IRF3

False positive plasma genotyping due to clonal hematopoiesis

Overcoming therapy resistance in EGFR-mutant lung cancer

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Thirty Years of HER3: From Basic Biology to Therapeutic Interventions

The biology and treatment of EML4-ALK non-small cell lung cancer

Targeting MET Dysregulation in Cancer

Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

TGFβ pathway inhibition in the treatment of non-small cell lung cancer

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Top advances of the year: Targeted therapy for lung cancer

Lung cancer in patients who have never smoked — an emerging disease

Suchergebnisse filtern